Elevated levels of pre-treatment lactate dehydrogenase are an unfavorable predictor factor in patients with EML4-ALK rearrangement non-small cell lung cancer treated with crizotinib

Elevated levels of pre-treatment lactate dehydrogenase are an unfavorable predictor factor in patients with EML4-ALK rearrangement non-small cell lung cancer treated with crizotinib

Hongge Liang1, Di Ma2, Yan Xu1, Jing Zhao1, Minjiang Chen1, Xiaoyan Liu1, Wei Zhong1, Junling Li2, Mengzhao Wang1 1Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, People’s Republic of China; 2Departm...

Full description

Bibliographic Details
Main Authors: Liang H, Ma D, Xu Y, Zhao J, Chen M, Liu X, Zhong W, Li J, Wang M
Format: Article
Language:English
Published: Dove Medical Press 2019-09-01
Series:Cancer Management and Research
Subjects:
non-small cell lung cancer
lactate dehydrogenase
crizotinib
echinoderm microtubule-associated protein-like 4-anaplasticlymphoma kinase
progression free survival.
Online Access:https://www.dovepress.com/elevated-levels-of-pre-treatment-lactate-dehydrogenase-are-an-unfavora-peer-reviewed-article-CMAR

Internet

https://www.dovepress.com/elevated-levels-of-pre-treatment-lactate-dehydrogenase-are-an-unfavora-peer-reviewed-article-CMAR

Similar Items